BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 23071679)

  • 1. Succession in the gut microbiome following antibiotic and antibody therapies for Clostridium difficile.
    Peterfreund GL; Vandivier LE; Sinha R; Marozsan AJ; Olson WC; Zhu J; Bushman FD
    PLoS One; 2012; 7(10):e46966. PubMed ID: 23071679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection.
    Reeves AE; Theriot CM; Bergin IL; Huffnagle GB; Schloss PD; Young VB
    Gut Microbes; 2011; 2(3):145-58. PubMed ID: 21804357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An in vitro culture model to study the dynamics of colonic microbiota in Syrian golden hamsters and their susceptibility to infection with Clostridium difficile.
    Miezeiewski M; Schnaufer T; Muravsky M; Wang S; Caro-Aguilar I; Secore S; Thiriot DS; Hsu C; Rogers I; DeSantis T; Kuczynski J; Probst AJ; Chehoud C; Steger R; Warrington J; Bodmer JL; Heinrichs JH
    ISME J; 2015 Feb; 9(2):321-32. PubMed ID: 25036923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of antibiotic therapy on human fecal microbiota and the relation to the development of Clostridium difficile.
    De La Cochetière MF; Durand T; Lalande V; Petit JC; Potel G; Beaugerie L
    Microb Ecol; 2008 Oct; 56(3):395-402. PubMed ID: 18209965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response of the gut microbiota during the Clostridioides difficile infection in tree shrews mimics those in humans.
    Gu W; Li W; Wang W; Kuang D; Zhang W; Lu C; Li N; Tong P; Han Y; Sun X; Lu J; Wu Y; Dai J
    BMC Microbiol; 2020 Aug; 20(1):260. PubMed ID: 32819295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and optimization of a novel assay to measure neutralizing antibodies against Clostridium difficile toxins.
    Xie J; Zorman J; Indrawati L; Horton M; Soring K; Antonello JM; Zhang Y; Secore S; Miezeiewski M; Wang S; Kanavage AD; Skinner JM; Rogers I; Bodmer JL; Heinrichs JH
    Clin Vaccine Immunol; 2013 Apr; 20(4):517-25. PubMed ID: 23389929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastrointestinal colonization with a cephalosporinase-producing bacteroides species preserves colonization resistance against vancomycin-resistant enterococcus and Clostridium difficile in cephalosporin-treated mice.
    Stiefel U; Nerandzic MM; Pultz MJ; Donskey CJ
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4535-42. PubMed ID: 24867962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
    Louie TJ; Cannon K; Byrne B; Emery J; Ward L; Eyben M; Krulicki W
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S132-42. PubMed ID: 22752862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clostridium difficile colonization in early infancy is accompanied by changes in intestinal microbiota composition.
    Rousseau C; Levenez F; Fouqueray C; Doré J; Collignon A; Lepage P
    J Clin Microbiol; 2011 Mar; 49(3):858-65. PubMed ID: 21177896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters.
    Torres JF; Lyerly DM; Hill JE; Monath TP
    Infect Immun; 1995 Dec; 63(12):4619-27. PubMed ID: 7591115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Initial Gut Microbiota and Response to Antibiotic Perturbation Influence Clostridioides difficile Clearance in Mice.
    Tomkovich S; Stough JMA; Bishop L; Schloss PD
    mSphere; 2020 Oct; 5(5):. PubMed ID: 33087520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microbiome data distinguish patients with Clostridium difficile infection and non-C. difficile-associated diarrhea from healthy controls.
    Schubert AM; Rogers MA; Ring C; Mogle J; Petrosino JP; Young VB; Aronoff DM; Schloss PD
    mBio; 2014 May; 5(3):e01021-14. PubMed ID: 24803517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters.
    Anosova NG; Brown AM; Li L; Liu N; Cole LE; Zhang J; Mehta H; Kleanthous H
    J Med Microbiol; 2013 Sep; 62(Pt 9):1394-1404. PubMed ID: 23518659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin.
    Warn P; Thommes P; Sattar A; Corbett D; Flattery A; Zhang Z; Black T; Hernandez LD; Therien AG
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6471-6482. PubMed ID: 27527088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of LFF571 in a hamster model of Clostridium difficile infection.
    Trzasko A; Leeds JA; Praestgaard J; Lamarche MJ; McKenney D
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4459-62. PubMed ID: 22644020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies.
    Marozsan AJ; Ma D; Nagashima KA; Kennedy BJ; Kang YK; Arrigale RR; Donovan GP; Magargal WW; Maddon PJ; Olson WC
    J Infect Dis; 2012 Sep; 206(5):706-13. PubMed ID: 22732923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis.
    Buffie CG; Jarchum I; Equinda M; Lipuma L; Gobourne A; Viale A; Ubeda C; Xavier J; Pamer EG
    Infect Immun; 2012 Jan; 80(1):62-73. PubMed ID: 22006564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B.
    Permpoonpattana P; Hong HA; Phetcharaburanin J; Huang JM; Cook J; Fairweather NF; Cutting SM
    Infect Immun; 2011 Jun; 79(6):2295-302. PubMed ID: 21482682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Murine Neonatal Fc Receptor Is Required for Transport of Immunization-Induced C. difficile-Specific IgG to the Gut and Protection against Disease but Does Not Affect Disease Susceptibility.
    Amadou Amani S; Lang GA; Ballard JD; Lang ML
    Infect Immun; 2021 Sep; 89(10):e0027421. PubMed ID: 34097471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with
    Džunková M; D'Auria G; Xu H; Huang J; Duan Y; Moya A; Kelly CP; Chen X
    Front Cell Infect Microbiol; 2016; 6():119. PubMed ID: 27757389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.